Email Updates

You are here

AVAC in the News

  • Mark Feinberg and Helen Rees joined Mitchell Warren for a webinar titled “Pandemic Vaccine Development and Lessons for COVID-19” in April 2020. It is part of the COVID-19 and HIV webinar series hosted by AVAC, which focuses on global advocacy for HIV prevention.

    June 29, 2020
    General
    POZ
  • Improving access to HIV prevention is critical if we want to see meaningful reductions in new infections. Although the adoption and use of oral pre-exposure prophylaxis (PrEP) has gradually increased, with an estimated half a million people initiating PrEP worldwide, we are far from achieving the global target of three million users by the end of 2020.

    June 24, 2020
    Differentiated Service Delivery
  • When Dázon Dixon Diallo began working to prevent the spread of HIV among women in 1985, she first had to convince them that they could get the infection. Even some HIV activists didn’t fully appreciate that women needed to be included in prevention efforts. Diallo founded an Atlanta-based organization called SisterLove to promote reproductive justice and to support women with or at risk of getting HIV/AIDS, expanding it to a program in South Africa, where today two-thirds of the people living with HIV are women. In the US, almost one in five new HIV diagnoses are among women.

    June 10, 2020
    Wired
  • We reflect on the events that led to the controversies and identified that scientific and ethical concerns raised by members of local communities at each of these sites were erased by trialists, causing crisis that led to premature shut down the early PrEP trials. In the aftermath of these trials, the World Health Organisation, UNAIDS, and AVAC developed ethics guidelines intended to recognize the concerns as authentic, and developed guidelines to improve researchers’ engagement of communities in biomedical HIV prevention trial design and implementation.

    June 5, 2020
    Global Bioethics
  • In just six months, the virus that causes COVID-19 has spread around the world, infected over 5 million people, and exacted devastating public health and economic tolls that are only just beginning. Unprecedented efforts to accelerate the development of a vaccine for the virus underscore the urgency of this public health crisis.

    May 27, 2020
    General
    Devex
  • While results for the long-acting HIV prevention medication cabotegravir are promising in men who have sex with men (MSM), there is still no data on this drug in women, begging the question of whether this will be another HIV prevention option that ends up being approved for only one population.

    May 19, 2020
    MedPage Today
  • A major clinical trial comparing ViiV Healthcare’s long-acting injectable cabotegravir dosed every eight weeks with daily oral Truvada (tenofovir disoproxil fumarate/emtricitabine) for use as pre-exposure prophylaxis (PrEP) against HIV halted its blinded, placebo-controlled phase early when cabotegravir was found highly effective at preventing acquisition of the virus among transgender women and cisgender men who have sex with men (MSM).

    May 18, 2020
    POZ
  • Taken every 2 months, the long-acting injectable drug cabotegravir prevented more HIV infections than daily oral pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC), according to newly announced results from a major Phase 3 study.

    May 18, 2020
    The BodyPro
  • While there is a need for COVID-19 research, it is also important not to erase other important public health issues, such as HIV. Let us not let COVID-19 make us abandon the efforts we have put into HIV research and implementation and stall the progress made this far.

    May 18, 2020
    The Times Malawi
  • Today, we honour HIV Vaccine Awareness Day, as we do every May 18. As an HIV prevention advocate, I want to celebrate and thank the Zambian government for hosting the Imbokodo study, one of only two ongoing HIV vaccine efficacy trials on the globe. As a nation, we should also thank the altruistic women who give their bodies, time and hope as trial participants so that this vaccine study might finally lead us on a path to ending HIV transmission.

    May 18, 2020
    Zambia Daily Mail

Pages